S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NYSE:PSN

Parsons (PSN) Competitors

$46.82
-0.07 (-0.15%)
(As of 06/9/2023 ET)
Compare
Today's Range
$46.52
$47.00
50-Day Range
$42.76
$46.88
52-Week Range
$36.10
$50.15
Volume
173,341 shs
Average Volume
391,919 shs
Market Capitalization
$4.91 billion
P/E Ratio
50.89
Dividend Yield
N/A
Price Target
$49.78

PSN vs. KD, AUR, TDCX, MDRX, EXPO, MMS, CNXC, VNT, DNB, and AFRM

Should you be buying Parsons stock or one of its competitors? The main competitors of Parsons include Kyndryl (KD), Aurora Innovation (AUR), TDCX (TDCX), Veradigm (MDRX), Exponent (EXPO), Maximus (MMS), Concentrix (CNXC), Vontier (VNT), Dun & Bradstreet (DNB), and Affirm (AFRM). These companies are all part of the "business services" sector.

Parsons vs.

Kyndryl (NYSE:KD) and Parsons (NYSE:PSN) are both mid-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Kyndryl currently has a consensus price target of $16.67, indicating a potential upside of 34.08%. Parsons has a consensus price target of $49.78, indicating a potential upside of 6.32%. Given Kyndryl's stronger consensus rating and higher probable upside, research analysts clearly believe Kyndryl is more favorable than Parsons.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyndryl
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Parsons
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14

Parsons has a net margin of 2.30% compared to Kyndryl's net margin of -8.07%. Parsons' return on equity of 8.38% beat Kyndryl's return on equity.

Company Net Margins Return on Equity Return on Assets
Kyndryl -8.07% -27.55% -4.29%
Parsons 2.30% 8.38% 4.12%

Parsons received 84 more outperform votes than Kyndryl when rated by MarketBeat users. Likewise, 53.42% of users gave Parsons an outperform vote while only 25.00% of users gave Kyndryl an outperform vote.

CompanyUnderperformOutperform
KyndrylOutperform Votes
2
25.00%
Underperform Votes
6
75.00%
ParsonsOutperform Votes
86
53.42%
Underperform Votes
75
46.58%

Parsons has lower revenue, but higher earnings than Kyndryl. Kyndryl is trading at a lower price-to-earnings ratio than Parsons, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyndryl$17.03 billion0.17-$1.38 billion-$6.06-2.05
Parsons$4.20 billion1.17$96.66 million$0.9250.89

Kyndryl has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Parsons has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

In the previous week, Parsons had 7 more articles in the media than Kyndryl. MarketBeat recorded 12 mentions for Parsons and 5 mentions for Kyndryl. Kyndryl's average media sentiment score of 1.27 beat Parsons' score of 0.80 indicating that Kyndryl is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyndryl
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Parsons
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

63.0% of Kyndryl shares are owned by institutional investors. Comparatively, 99.6% of Parsons shares are owned by institutional investors. 0.2% of Kyndryl shares are owned by insiders. Comparatively, 0.9% of Parsons shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Parsons beats Kyndryl on 13 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PSN vs. The Competition

MetricParsonsComputer integrated systems design IndustryBusiness SectorNYSE Exchange
Market Cap$4.91B$2.21B$5.08B$14.99B
Dividend YieldN/A1.34%4.96%3.85%
P/E Ratio50.8912.25225.1219.31
Price / Sales1.1711.34117.469.28
Price / Cash16.4913.42275.4124.62
Price / Book2.313.384.567.33
Net Income$96.66M$35.57M$121.67M$900.99M
7 Day Performance1.83%2.08%1.03%1.75%
1 Month Performance4.04%8.28%2.57%3.87%
1 Year Performance21.74%-3.09%-6.87%-2.53%

Parsons Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KD
Kyndryl
2.1 of 5 stars
$12.55
+3.0%
$16.67
+32.9%
+22.2%$2.86B$17.03B-2.0790,000Positive News
AUR
Aurora Innovation
2 of 5 stars
$1.52
+1.3%
$5.25
+245.4%
-13.6%$1.79B$68M-0.941,700Analyst Report
Positive News
TDCX
TDCX
2.5212 of 5 stars
$9.71
+5.7%
$11.40
+17.4%
-9.3%$1.39B$493.92M17.9817,883
MDRX
Veradigm
2.5786 of 5 stars
$11.95
+2.6%
$19.58
+63.9%
-30.6%$1.27B$1.53B27.798,000News Coverage
EXPO
Exponent
2.1825 of 5 stars
$95.41
+2.2%
$99.00
+3.8%
+10.4%$4.85B$525.12M48.681,313
MMS
Maximus
2.6994 of 5 stars
$82.62
+1.7%
$100.00
+21.0%
+37.1%$4.94B$4.76B29.4039,500Positive News
CNXC
Concentrix
3.0635 of 5 stars
$91.80
+5.3%
$160.00
+74.3%
-46.5%$4.78B$6.32B11.66315,000
VNT
Vontier
2.1823 of 5 stars
$30.65
+2.1%
$28.83
-5.9%
+18.0%$4.77B$3.18B20.578,100
DNB
Dun & Bradstreet
2.6358 of 5 stars
$10.80
+3.4%
$15.75
+45.9%
-30.2%$4.74B$2.22B-1,079.506,355News Coverage
AFRM
Affirm
1.3882 of 5 stars
$15.82
+1.7%
$16.21
+2.4%
-17.9%$4.68B$1.35B-4.792,552Options Volume
Analyst Revision
News Coverage

Related Companies and Tools

This page (NYSE:PSN) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -